Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses
Open Access
- 1 January 2009
- journal article
- Published by Springer Nature in BMC Immunology
- Vol. 10 (1), 19
- https://doi.org/10.1186/1471-2172-10-19
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysisBMC Endocrine Disorders, 2008
- Stromal cell‐derived factors 1α and 1β, inflammatory protein‐10 and interferon‐inducible T cell chemo‐attractant are novel substrates of dipeptidyl peptidase 8FEBS Letters, 2008
- On the role of CD26 in CD4 memory T cellsImmunobiology, 2007
- Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptinBioorganic & Medicinal Chemistry Letters, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetesEmerging Drugs, 2006
- 3D structure of the CD26–ADA complex obtained by cryo-EM and single particle analysisBiochemical and Biophysical Research Communications, 2004
- Regulation of the Receptor Specificity and Function of the Chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) by Dipeptidyl Peptidase IV (CD26)-mediated CleavageThe Journal of Experimental Medicine, 1997
- Suppression of arthritis by the inhibitors of dipeptidyl peptidase IVInternational Journal of Immunopharmacology, 1997